Hypopigmentation from Imatinib Mesylate (Gleevec)

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 3, 2004, Pages 214-

  Grossman, William J ^a   Wilson, David B ^a  

^a ST LOUIS CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

ACUTE LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILD; HIGH RISK POPULATION; HUMAN; HYPOPIGMENTATION; MALE; PATHOGENESIS; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL;

EID: 1542316943     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200403000-00016     Document Type: Article

References (6)

1. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000;295:139-145.
2. Fleischman RA, Saltman DL, Stastny V, et al. Deletion of the c-kit protooncogene in the human developmental defect piebald trait. Proc Natl Acad Sci USA. 1991;88:10885-10889.
3. Spritz RA. Molecular basis of human piebaldism. J Invest Dermatol. 1994;103:137S-140S.
4. Yoshida H, Kunisada T, Grimm T, et al. Review: melanocyte migration and survival controlled by SCF/c-kit expression. J Invest Dermatol Symp Proc. 2001;6:1-5.
5. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med. 2001;345:618-619.
6. Hasan S, Dinh K, Lombardo F, et al. Hypopigmentation in an African patient treated with imatinib mesylate: a case report. J Natl Med Assoc. 2003;95:722-724.